Thus, identifying new MSA may help in monitoring PM/DM patients and several new clinically significant autoantibodies associated with DM including anti-p155/140 [5-11], anti-CADM (clinically amyopathic DM) 140/MDA5 (melanoma differentiation associated antigen 5) [10,12-14], anti-SAE (small ubiquitin-like molecule activating enzyme) and anti-MJ/NXP-2 have been reported recently [15,16]. Here, IFIH1 is linked to dermatomyositis.